NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
Clinical Trials
922 trialsNCT00026884 2026-04-14
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
National Institutes of Health Clinical Center (CC)
Recruiting
NCT00033137 2026-04-14
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
National Institutes of Health Clinical Center (CC)
Recruiting
NCT00050752 2026-04-14
Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
National Institutes of Health Clinical Center (CC)
Recruiting
NCT01109394 2026-04-14
Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies
National Institutes of Health Clinical Center (CC)
Recruiting
NCT03091192 2026-04-14
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Phase 3 Active not recruiting
NCT03846128 2026-04-14
BIOSUNTOX
University Hospital, Rouen
Terminated
NCT06026410 2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06525831 2026-04-14
Rein3DP-M
University Hospital, Bordeaux
Phase NA Recruiting
NCT07117227 2026-04-14
RCCETT
Peking University Third Hospital
Recruiting
NCT07527637 2026-04-14
Risk of Scrotal Hydroceles After Nephrectomy For Kidney Cancer
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Completed
NCT05210933 2026-04-13
SMART
University of Alberta
Suspended
NCT05969496 2026-04-13
NEOPAX
University of Colorado, Denver
Phase 2 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT02087852 2026-04-09
Kidney Cancer DNA Registry
Memorial Sloan Kettering Cancer Center
Recruiting
NCT00579514 2026-04-07
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT05665361 2026-04-07
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT07195682 2026-04-07
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07227415 2026-04-07
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT02964078 2026-04-02
Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT07401875 2026-04-02
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06532422 2026-04-01
NEPHRAMBU
GCS Ramsay Santé pour l'Enseignement et la Recherche
Recruiting
NCT06948552 2026-04-01
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
Henry Ford Health System
Phase 2 Recruiting
NCT07011719 2026-04-01
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3 Recruiting
NCT07197580 2026-04-01
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT07234656 2026-04-01
PP-RECURK
Gødstrup Hospital
Recruiting
NCT00001238 2026-03-31
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
National Institutes of Health Clinical Center (CC)
Recruiting
NCT03786796 2026-03-30
ORCHID
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT05536141 2026-03-30
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT07123090 2026-03-25
SPARCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05700461 2026-03-20
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
Phase 1 Enrolling by invitation
NCT06126159 2026-03-20
MRI Functional Imaging Characteristics and Fat Quantification of CT-fat-free Renal Neoplasms: Relationships With Histological Classifications and Molecular Markers
Chang Gung Memorial Hospital
Phase NA Active not recruiting
NCT06882486 2026-03-20
NAMECAR
Institut Paoli-Calmettes
Phase NA Recruiting
NCT07397611 2026-03-20
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07485114 2026-03-20
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Tel-Aviv Sourasky Medical Center
Recruiting
NCT03185039 2026-03-19
Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents
Institut Paoli-Calmettes
Phase NA Active not recruiting
NCT07004426 2026-03-19
KIDCaD
Charles University, Czech Republic
Completed
NCT05384821 2026-03-18
MetroWilms
Centre Oscar Lambret
Phase 1/2 Recruiting
NCT05888532 2026-03-17
64Cu-GRIP B in Patients With Advanced Malignancies
University of California, San Francisco
Phase 1/2 Recruiting
NCT02121730 2026-03-16
FRISC
Centre Hospitalier Universitaire, Amiens
Completed
NCT02439008 2026-03-13
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
Centre Oscar Lambret
Phase NA Terminated
NCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
NCT03996850 2026-03-13
SPECT/CT for the Characterization of Renal Masses
Jonsson Comprehensive Cancer Center
Active not recruiting
NCT07284953 2026-03-13
PuraBond
The Royal Wolverhampton Hospitals NHS Trust
Phase NA Withdrawn
NCT03239145 2026-03-12
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Phase 1 Completed
NCT07050771 2026-03-12
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT04987086 2026-03-11
68Ga-PSMA PET in the Renal Cell Carcinoma
Xijing Hospital
Phase NA Recruiting
NCT07077083 2026-03-11
CAIX PET/CT
Massachusetts General Hospital
Phase 2 Not yet recruiting